Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies-Reference-Cited by-同舟云学术

Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategies

Published:2021-01 Issue: Volume:15 Page:175346662110425
ISSN:1753-4666
Container-title:Therapeutic Advances in Respiratory Disease
language:en
Short-container-title:Ther Adv Respir Dis

Author:

Canonica Giorgio Walter¹²^ORCID,Paggiaro Pierluigi³^ORCID,Blasi Francesco⁴⁵,Musarra Antonino⁶,Richeldi Luca⁷,Rossi Andrea⁸,Papi Alberto⁹

Affiliation:

1. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy

2. IRCCS Humanitas Research Hospital, Personalized Medicine, Asthma and Allergy, via Manzoni 56, 20089 Rozzano, Milan, Italy

3. Department of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, Pisa, Italy

4. Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Respiratory Unit and Cystic Fibrosis Adult Center, Milan, Italy

5. Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

6. Allergy Unit, National Health Service, Scilla, Italy

7. Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

8. Pulmonary Unit, Azienda Ospedaliera Universitaria Integrata and University of Verona, Verona, Italy

9. Research Center on Asthma and COPD, Department of Translational Medicine, University of Ferrara, Ferrara, Italy

Abstract

The risks of overusing short-acting β2-agonists (SABA), including an increase in asthma-related deaths, are many and well known. The Global Initiative on Asthma (GINA) 2019 and 2020 updates recommend as-needed inhaled corticosteroid (ICS)/formoterol as the preferred rescue medication in mild asthma as monotherapy and also in moderate to severe asthma when the maintenance and reliever therapy (MART) strategy is used. Using SABA for symptom relief, however, was the standard of treatment for many years, and consequently this practice persists, particularly in patients not taking ICS regularly. Here, we examine the rationale for this shift from a long-standing recommendation for as-needed SABA treatment to the use of as-needed ICS/formoterol and consider clinical evidence on strategies for asthma treatment and patient management.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Pulmonary and Respiratory Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/17534666211042534

Reference39 articles.

1. SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β2-agonist use in asthma

2. The paradoxes of asthma management: time for a new approach?

3. GINA 2019: a fundamental change in asthma management

4. The further paradoxes of asthma management: time for a new approach across the spectrum of asthma severity

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A very rare case of anomalous systemic arterial supply to lung without sequestration;Lung India;2024-04-30

2. Call to action: Addressing asthma diagnosis and treatment gaps in India;Lung India;2024-04-30

3. The Association Between Short-Acting β2-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia;Advances in Therapy;2024-02-04

4. Towards net zero: asthma care;BMJ;2023-06-19

5. SABAs as Reliever Medications in Asthma Management: Evidence-Based Science;Advances in Therapy;2023-06-07